12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Masitinib: Phase III data

A double-blind, international Phase III trial in 348 patients with pancreatic cancer showed that masitinib plus Gemzar gemcitabine missed the primary endpoint of median OS vs. placebo plus Gemzar (7.7 vs. 7 months, p=0.74). In a subgroup of patients with an undisclosed genetic biomarker that the company said is indicative of aggressive disease progression, masitinib plus Gemzar significantly improved median OS vs. placebo plus Gemzar (11 vs. 5 months, p=0.000038). In this population, masitinib plus Gemzar...

Read the full 370 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >